All big drugmakers have already reported this earnings season and so have some smaller drug and biotech companies.Majority of the companies beat estimates for both earnings and sales. Almost all companies witnessed a recovery in sales of their key products/drugs from the earlier impacts of the pandemic in the second quarter and sounded optimistic of continued improvement in the second half. Some companies like J&J and Pfizer raised their expectations for both earnings and sales.There are, however, some smaller biotechs which are yet to report.Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies.Per the Earnings Trends report as of Aug 4, 70.9% of the companies in the Medical sector, constituting nearly 81.9% of the sector’s market capitalization, reported earnings. While 89.7% beat earnings estimates, 97.4% beat the same for sales. Earnings increased 17.7% year over year on 20.3% higher revenues. Overall, second-quarter earnings for the Medical sector are expected to rise 25.7% on 19.2% sales increase.Zeroing in on WinnersHere we have highlighted five drug/biotech companies — F-star Therapeutics FSTX, Halozyme Therapeutics HALO, Kinnate Biopharma KNTE, Rubius Therapeutics RUBY and Spruce Biosciences SPRB — which are expected to deliver a beat in their upcoming quarterly results.Earnings ESP is our proprietary methodology for determining the stocks that have the best chance to deliver an earnings surprise. Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be done with the help of the Zacks Stock Screener.Our research shows that for stocks with this combination, the chance of an earnings surprise is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.5 Drug/Biotech Stocks That Match the CriteriaF-star Therapeutics This Cambridge, MA-based biotech, has an Earnings ESP of +13.44% and a Zacks Rank of 3. The Zacks Consensus Estimate for the second quarter is pegged at a loss of 77 cents per share. The company is scheduled to release results on Aug 12You can see the complete list of today’s Zacks #1 Rank stocks hereIn November last year, F-star Therapeutics merged with Spring Bank Pharmaceuticals and began trading on The Nasdaq from Nov 23. In the first quarter of 2021, the company delivered an earnings surprise of 14.3%.Fstar Therapeutics, Inc. Price and EPS Surprise Fstar Therapeutics, Inc. price-eps-surprise | Fstar Therapeutics, Inc. QuoteHalozyme Therapeutics This San Diego, CA-based biotech has an Earnings ESP of +52.1% and a Zacks Rank #3. The Zacks Consensus Estimate for the second quarter is pegged at earnings of 43 cents per share. Halozyme beat estimates in two of the last four quarters while missing in the other two with the average surprise being 2.41%. The company is scheduled to release results on Aug 9.Halozyme Therapeutics, Inc. Price and EPS Surprise Halozyme Therapeutics, Inc. price-eps-surprise | Halozyme Therapeutics, Inc. QuoteKinnate Biopharma This San Diego, CA-based biotech has as an Earnings ESP of +1.15% and a Zacks Rank of #3. The Zacks Consensus Estimate for the second quarter is pegged at a loss of 44 cents per share.The company closed its initial public offering (IPO) of shares in December and the stock began trading on The Nasdaq from Dec 3, 2020.In the first quarter of 2021, the company delivered a negative earnings surprise of 8.11%.Kinnate Biopharma Inc. Price and EPS Surprise Kinnate Biopharma Inc. price-eps-surprise | Kinnate Biopharma Inc. QuoteRubius Therapeutics This Cambridge, MA biotech has as an Earnings ESP of +15.29% and a Zacks Rank of #3. The Zacks Consensus Estimate for the second quarter is pegged at a loss of 48 cents per share. The company is scheduled to release results on Aug 9.In the trailing four quarters, Rubius Therapeutics missed estimates in one quarter and beat in the other three with the average surprise being 5.55%.Rubius Therapeutics, Inc. Price and EPS Surprise Rubius Therapeutics, Inc. price-eps-surprise | Rubius Therapeutics, Inc. QuoteSpruce BiosciencesThis Daly City, CA-based late-stage biotech has as an Earnings ESP of +8.21% and a Zacks Rank of #3. The Zacks Consensus Estimate for the second quarter is pegged at a loss of 45 cents per share.In the trailing three quarters, Spruce Biosciences missed estimates in one quarter and beat in the other two with the average negative surprise being 207.6%. The company closed its IPO in October last year and the stock began trading on The Nasdaq from Oct 9, 2020.Spruce Biosciences, Inc. Price and EPS Surprise Spruce Biosciences, Inc. price-eps-surprise | Spruce Biosciences, Inc. Quote Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is “Will you get into the right stocks early when their growth potential is greatest?” Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.Download FREE: How to Profit from Trillions on Spending for Infrastructure >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report Rubius Therapeutics, Inc. (RUBY): Free Stock Analysis Report Spruce Biosciences, Inc. (SPRB): Free Stock Analysis Report Fstar Therapeutics, Inc. (FSTX): Free Stock Analysis Report Kinnate Biopharma Inc. (KNTE): Free Stock Analysis Report To read this article on Zacks.com click here.